New Recruiting Trial: A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

WHY IT MATTERS

This trial offers access to a novel EGFR-targeted therapy for patients with EGFR-mutant lung or head and neck cancers who may have limited treatment options or resistance to current therapies.

Researchers are testing a new experimental drug called EPI-326 in people with two types of cancer: non-small cell lung cancer and head and neck cancer, both caused by mutations in the EGFR gene. This is an early-stage study (Phase 1) to see if the drug is safe and how much patients can tolerate. The study is currently accepting new participants and is expected to start in April 2026.

NCT ID: NCT07462377 Title: A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC Status: RECRUITING Phase: PHASE1 Sponsor: EpiBiologics Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07462377 Source: UniteRare clinical trials database

ASK YOUR DOCTOR

Ask your oncologist if you have EGFR-mutant NSCLC or HNSCC and whether you might be eligible for this trial—eligibility criteria and participating sites are available on ClinicalTrials.gov (NCT07462377).